C188-9 is an orally bioavailable STAT3 inhibitor that exhibits in vitro and in vivo activity against preclinical models of non-small cell lung cancer [42], head and neck squamous cell carcinoma [41], liver cancer [43], and breast cancer [44]. This evidence concerns the gene STAT3 and breast cancer.